NuraLogix has enhanced its Anura contactless health monitoring platform with the ability to perform metabolic and blood biomarker health risk assessments for various chronic conditions.
The new capabilities will be showcased by the company at the upcoming MWC 2023 in Barcelona, Spain.
Using mobile and desktop devices, the Anura platform can be used to assess chronic conditions like HbA1c and fasting glucose, and the risk of type 2 diabetes, hypertriglyceridemia, and hypertension.
Anura is said to be a video-based contactless health monitoring technology that can monitor vital signs and offer health risk assessments. It uses video selfies to detect blood flow, as opposed to smartwatches, fitness trackers, and rings that use light sensors.
The platform can help the mobile industry to incorporate digital health solutions into the healthcare business as well as industries like retail, automotive, and smart cities.
Canada-based NuraLogix said that Anura is now able to give over 30 health metrics. It enables third-party clients including wellness programmes, insurance providers, and health professionals to assist consumers in better managing their physical and mental health.
NuraLogix chief medical officer Keith Thompson said: “The wireless industry has already played an important role in remote and novel health solutions, and with 5G adoption increasing, its ability to power the health industry is accelerating.
“Platforms such as Anura allow handset manufacturers and carriers to create or work with additional third parties to deploy digital health solutions that can make a meaningful difference to society.
“Our agnostic hardware and operating system approach paves the way to a world where health vitals are continually monitored with just a look at a smartphone, bathroom mirror, TV screen, or kiosk.”
Founded in 2015, NuraLogix has designed the platform using its patented Transdermal Optical Imaging (TOI) technology, a form of Remote Photoplethysmography (rPPG).
The platform utilises artificial intelligence (AI) data models created from patients with various health conditions to automatically detect a person’s face, identify important regions of interest, and extract information about blood flow, the Canadian firm added.
